PT - JOURNAL ARTICLE AU - Sally Hallam AU - Joanne Stockton AU - Claire Bryer AU - Celina Whalley AU - Valerie Pestinger AU - Haney Youssef AU - Andrew D Beggs TI - The transition from primary colorectal cancer to isolated peritoneal malignancy is associated with a hypermutant, hypermethylated state AID - 10.1101/2020.02.24.20027318 DP - 2020 Jan 01 TA - medRxiv PG - 2020.02.24.20027318 4099 - http://medrxiv.org/content/early/2020/02/25/2020.02.24.20027318.short 4100 - http://medrxiv.org/content/early/2020/02/25/2020.02.24.20027318.full AB - Coloretcal Peritoneal metastases (CPM) develop in 15% of colorectal cancers. Cytoreductive surgery and heated intraperitoneal chemotherapy (CRS & HIPEC) is the current standard of care in selected patients with limited resectable CPM. Despite selection using known prognostic factors survival is varied and morbidity and mortality are relatively high. There is a need to improve patient selection and a paucity of research concerning the biology of isolated CPM. We aimed to determine the biology associated with transition from primary CRC to CPM and poor prognosis CPM, to identify those suitable for treatment with CRS & HIPEC and to identify targets for existing repurposed or novel treatment strategies. A cohort of patients with CPM treated with CRS & HIPEC was recruited and divided according to prognosis. Molecular profiling of the transcriptome, epigenome and genome of CPM and matched primary CRC was performed.CPM were characterised by frequent Wnt/ β catenin negative regulator mutations, mismatch repair mutations and resulting high tumour mutational burden and dysregulation of methylation suggested by frequent TET2 mutations and mutations suggesting an immune evasive phenotype. Several novel therapies could be targeted to these frequent mutations including porcupine inhibitors, immune checkpoint inhibitors and methylation inhibitors. Here we show the molecular features associated with CPM development and with poor prognosis. Potential applications include improving patient selection for treatment and in the development of novel and personalised treatments.NOVELTY AND IMPACT Colorectal peritoneal metastasis (CPM) are associated with limited and variable survival despite patient selection using known prognostic factors and optimal currently available treatments. There is a paucity of research concerning the biology of CPM. This study describes the biological landscape of CPM and the molecular features associated with CPM development, conferring poor prognosis and has identified that the majority of CPM develop a hypermutant phenotype that may be suitable for treatment with anti-PD1/CTLA4 immunotherapy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementADB is currently supported by a Cancer Research UK Advanced Clinician Scientist award (ref C31641/A23923). This project was supported by a consumables award from the Good Hope Hospital CharityAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be deposited onto SRA on acceptance of manuscript